|
1
|
Favre-Kontula L, Rolland A, Bernasconi L,
Karmirantzou M, Power C, Antonsson B and Boschert U: GlialCAM, an
immunoglobulin-like cell adhesion molecule is expressed in glial
cells of the central nervous system. Glia. 56:633–645. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chung Moh M, Hoon Lee L and Shen S:
Cloning and charac-terization of hepaCAM, a novel Ig-like cell
adhesion molecule suppressed in human hepatocellular carcinoma. J
Hepatol. 42:833–841. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moh MC, Zhang C, Luo C, Lee LH and Shen S:
Structural and functional analyses of a novel Ig-like cell adhesion
molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol
Chem. 280:27366–27374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moh MC, Zhang T, Lee LH and Shen S:
Expression of hepaCAM is downregulated in cancers and induces
senescence-like growth arrest via a p53/p21-dependent pathway in
human breast cancer cells. Carcinogenesis. 29:2298–2305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee LH, Moh MC, Zhang T and Shen S: The
immunoglobulin-like cell adhesion molecule hepaCAM induces
differentiation of human glioblastoma U373-MG cells. J Cell
Biochem. 107:1129–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xun C, Luo C, Wu X, Zhang Q, Yan L and
Shen S: Expression of hepaCAM and its effect on proliferation of
tumor cells in renal cell carcinoma. Urology. 75:828–834. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang QL, Luo CL, Wu XH, Wang CY, Xu X,
Zhang YY, Liu Q and Shen SL: HepaCAM induces G1 phase arrest and
promotes c-Myc degradation in human renal cell carcinoma. J Cell
Biochem. 112:2910–2919. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He Y, Wu X, Luo C, Wang L and Lin J:
Functional significance of the hepaCAM gene in bladder cancer. BMC
Cancer. 10:832010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu X, Shan L, Wang F, Wang J, Wang F,
Shen G, Liu X, Wang B, Yuan Y, Ying J, et al: Hypermethylation of
BRCA1 gene: Implication for prognostic biomarker and therapeutic
target in sporadic primary triple-negative breast cancer. Breast
Cancer Res Treat. 150:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed IA, Pusch CM, Hamed T, Rashad H,
Idris A, El-Fadle AA and Blin N: Epigenetic alterations by
methylation of RASSF1A and DAPK1 promoter sequences in mammary
carcinoma detected in extracellular tumor DNA. Cancer Genet
Cytogenet. 199:96–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang G, Chan MF, Tomigahara Y, Tsai YC,
Gonzales FA, Li E, Laird PW and Jones PA: Cooperativity between DNA
methyltransferases in the maintenance methylation of repetitive
elements. Mol Cell Biol. 22:480–491. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramos MP, Wijetunga NA, McLellan AS,
Suzuki M and Greally JM: DNA demethylation by
5-aza-2′-deoxycytidine is imprinted, targeted to euchromatin, and
has limited transcriptional consequences. Epigenetics Chromatin.
8:112015. View Article : Google Scholar
|
|
13
|
Amara K, Ziadi S, Hachana M, Soltani N,
Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein
over-expression as a prognostic factor in patients with diffuse
large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen MF, Chen WC, Chang YJ, Wu CF and Wu
CT: Role of DNA methyltransferase 1 in hormone-resistant prostate
cancer. J Mol Med Berl. 88:953–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Devanand P, Kim SI, Choi YW, Sheen SS, Yim
H, Ryu MS, Kim SJ, Kim WJ and Lim IK: Inhibition of bladder cancer
invasion by Sp1-mediated BTG2 expression via inhibition of DNA
methyltransferase 1. FEBS J. 281:5581–5601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brueckner B and Lyko F: DNA
methyltransferase inhibitors: Old and new drugs for an epigenetic
cancer therapy. Trends Pharmacol Sci. 25:551–554. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wijermans P, Lübbert M, Verhoef G, Bosly
A, Ravoet C, Andre M and Ferrant A: Low-dose
5-aza-2′-deoxycytidine, a DNA hypo-methylating agent, for the
treatment of high-risk myelodysplastic syndrome: A multicenter
phase II study in elderly patients. J Clin Oncol. 18:956–962.
2000.PubMed/NCBI
|
|
18
|
Issa JP, Garcia-Manero G, Giles FJ,
Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS,
Cortes J, et al: Phase 1 study of low-dose prolonged exposure
schedules of the hypomethylating agent 5-aza-2′-deoxycytidine
(decitabine) in hematopoietic malignancies. Blood. 103:1635–1640.
2004. View Article : Google Scholar
|
|
19
|
Xu B, He Y, Wu X, Luo C, Liu A and Zhang
J: Exploration of the correlations between interferon-γ in patient
serum and HEPACAM in bladder transitional cell carcinoma, and the
interferon-γ mechanism inhibiting BIU-87 proliferation. J Urol.
188:1346–1353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Luo C, Wu X, Du H, Song X and Fan
Y: hepaCAM and p-mTOR closely correlate in bladder transitional
cell carcinoma and hepaCAM expression inhibits proliferation via an
AMPK/mTOR dependent pathway in human bladder cancer cells. J Urol.
190:1912–1918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alexander VM, Roy M, Steffens KA,
Kunnimalaiyaan M and Chen H: Azacytidine induces cell cycle arrest
and suppression of neuroendocrine markers in carcinoids. Int J Clin
Exp Med. 3:95–102. 2010.PubMed/NCBI
|
|
22
|
Pasin E, Josephson DY, Mitra AP, Cote RJ
and Stein JP: Superficial bladder cancer: An update on etiology,
molecular development, classification, and natural history. Rev
Urol. 10:31–43. 2008.PubMed/NCBI
|
|
23
|
Zeegers MP, Kellen E, Buntinx F and van
den Brandt PA: The association between smoking, beverage
consumption, diet and bladder cancer: A systematic literature
review. World J Urol. 21:392–401. 2004. View Article : Google Scholar
|
|
24
|
Scrima M, De Marco C, De Vita F, Fabiani
F, Franco R, Pirozzi G, Rocco G, Malanga D and Viglietto G: The
nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor
gene in non-small cell lung cancer. Am J Pathol. 180:1202–1214.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoon JI, Kim SI, Tommasi S and Besaratinia
A: Organ specificity of the bladder carcinogen 4-aminobiphenyl in
inducing DNA damage and mutation in mice. Cancer Prev Res (Phila).
5:299–308. 2012. View Article : Google Scholar
|
|
26
|
Kandimalla R, van Tilborg AA and Zwarthoff
EC: DNA methylation-based biomarkers in bladder cancer. Nat Rev
Urol. 10:327–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bilgrami SM, Qureshi SA, Pervez S and
Abbas F: Promoter hypermethylation of tumor suppressor genes
correlates with tumor grade and invasiveness in patients with
urothelial bladder cancer. Springerplus. 3:1782014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li G, Liu Y, Yin H, Zhang X, Mo X, Tang J
and Chen W: E-cadherin gene promoter hypermethylation may
contribute to the risk of bladder cancer among Asian populations.
Gene. 534:48–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Piaton E, Casalegno JS, Advenier AS,
Decaussin-Petrucci M, Mege-Lechevallier F, Ruffion A and Mekki Y:
p16(INK4a) over-expression is not linked to oncogenic human
papillomaviruses in patients with high-grade urothelial cancer
cells. Cancer Cytopathol. 122:760–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pan C, Wu X, Luo C, Yang S, Pu J, Wang C
and Shen S: Exon 2 methylation inhibits hepaCAM expression in
transitional cell carcinoma of the bladder. Urol Int. 85:347–354.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
32
|
Stutterheim J, Ichou FA, den Ouden E,
Versteeg R, Caron HN, Tytgat GA and van der Schoot CE: Methylated
RASSF1a is the first specific DNA marker for minimal residual
disease testing in neuroblastoma. Clin Cancer Res. 18:808–814.
2012. View Article : Google Scholar
|
|
33
|
Tian X, Chen D, Zhang R, Zhou J, Peng X,
Yang X, Zhang X and Zheng Z: Quantitative survey of multiple CpGs
from 5 genes identifies CpG methylation panel discriminating
between high- and low-grade cervical intraepithelial neoplasia.
Clin Epigenetics. 7:42015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jing H, Dai F, Zhao C and Yang J, Li L,
Kota P, Mao L, Xiang K, Zheng C and Yang J: Association of genetic
variants in and promoter hypermethylation of CDH1 with gastric
cancer: A meta-analysis. Medicine (Baltimore). 93:e1072014.
View Article : Google Scholar
|
|
35
|
Ding WJ, Fang JY, Chen XY and Peng YS: The
expression and clinical significance of DNA methyltransferase
proteins in human gastric cancer. Dig Dis Sci. 53:2083–2089. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He S, Wang F, Yang L, Guo C, Wan R, Ke A,
Xu L, Hu G, Xu X, Shen J, et al: Expression of DNMT1 and DNMT3a are
regulated by GLI1 in human pancreatic cancer. PLoS One.
6:e276842011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Agarwal S, Amin KS, Jagadeesh S, Baishay
G, Rao PG, Barua NC, Bhattacharya S and Banerjee PP: Mahanine
restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in
prostate cancer cells. Mol Cancer. 12:99–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fenaux P, Mufti GJ, Hellstrom-Lindberg E,
Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz
G, List A, et al International Vidaza High-Risk MDS Survival Study
Group: Efficacy of azacitidine compared with that of conventional
care regimens in the treatment of higher-risk myelodysplastic
syndromes: A randomised, open-label, phase III study. Lancet Oncol.
10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Borodovsky A, Salmasi V, Turcan S, Fabius
AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan
TA, et al: 5-Azacytidine reduces methylation, promotes
differentiation and induces tumor regression in a patient-derived
IDH1 mutant glioma xenograft. Oncotarget. 4:1737–1747. 2013.
View Article : Google Scholar : PubMed/NCBI
|
